A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Roche's patent deal with Structure; AstraZeneca reports lupus data
Roche's patent deal with Structure; AstraZeneca reports lupus data
Protagonist 'strongly leaning' toward opting out of Takeda profit-sharing deal
Protagonist 'strongly leaning' toward opting out of Takeda profit-sharing deal
Lilly goes back to Nimbus for an oral obesity drug in $55M deal
Lilly goes back to Nimbus for an oral obesity drug in $55M deal
Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data
Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data
Appeals court rules against NIH’s indirect cost cut plan
Appeals court rules against NIH’s indirect cost cut plan
FDA raises new questions with Sanofi's MS drug in release of rejection letter
FDA raises new questions with Sanofi's MS drug in release of rejection letter
HHS urges Supreme Court to decline AstraZeneca's petition over Medicare price negotiations
HHS urges Supreme Court to decline AstraZeneca's petition over Medicare price negotiations
US to stop recommending six vaccines for all kids, prioritizing individual choice and higher-risk groups
US to stop recommending six vaccines for all kids, prioritizing individual choice and higher-risk groups
Crinetics reports robust full-quarter sales for rare disease drug Palsonify
Crinetics reports robust full-quarter sales for rare disease drug Palsonify
Zenas BioPharma’s Phase 3 autoimmune disease readout disappoints
Zenas BioPharma’s Phase 3 autoimmune disease readout disappoints
Moderna seeks flu vaccine approvals; Neumora Alzheimer's data
Moderna seeks flu vaccine approvals; Neumora Alzheimer's data
Argenx to elevate Massey to CEO as it expands rare disease business
Argenx to elevate Massey to CEO as it expands rare disease business
Sanofi doubles down on Earendil in $160M near-term deal
Sanofi doubles down on Earendil in $160M near-term deal
Aktis Oncology eyes $181M listing to start industry’s anticipated IPO rebound
Aktis Oncology eyes $181M listing to start industry’s anticipated IPO rebound
Comanche gets $40M more to test its preeclampsia siRNA
Comanche gets $40M more to test its preeclampsia siRNA
Servier taps Insilico’s AI platform for early cancer R&D
Servier taps Insilico’s AI platform for early cancer R&D
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug
AbbVie does T cell engager deal in China for Zelgen's DLL3-targeted drug
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page